Skip to content
10-Q

Quarterly Report

BioXcel Therapeutics, Inc. BTAI

0001104659-25-109880

← back to feed
Filed
Nov 12, 2025 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2025 · Nov 11, 2025 21.87M sh
Shares Diluted Q3 2025 · Sep 30, 2025 14.2M sh
Shares Diluted Q3 2025 · Sep 30, 2025 8.99M sh
Shares Diluted restated Q3 2025 · Sep 30, 2024 2.65M sh
Shares Diluted restated Q3 2025 · Sep 30, 2024 2.37M sh
Capex Q3 2025 · Sep 30, 2025 $0
Capex Q3 2025 · Sep 30, 2024 $0
Operating Cash Flow Q3 2025 · Sep 30, 2025 −$43.41M
Operating Cash Flow Q3 2025 · Sep 30, 2024 −$57.22M
Long Term Debt Q3 2025 · Sep 30, 2025 $92.3M
Long Term Debt Q3 2025 · Dec 31, 2024 $102.51M
Short Term Debt Q3 2025 · Sep 30, 2025 $16.82M
Short Term Debt Q3 2025 · Dec 31, 2024 $0
Cash And Equivalents Q3 2025 · Sep 30, 2025 $36.18M
Cash And Equivalents Q3 2025 · Dec 31, 2024 $29.85M
Cash And Equivalents Q3 2025 · Sep 30, 2024 $40.39M
Stockholders Equity Q3 2025 · Sep 30, 2025 −$88.92M
Stockholders Equity Q3 2025 · Jun 30, 2025 −$107.67M
Stockholders Equity Q3 2025 · Mar 31, 2025 −$90.17M
Stockholders Equity Q3 2025 · Dec 31, 2024 −$93.1M
Stockholders Equity Q3 2025 · Sep 30, 2024 −$85.63M
Stockholders Equity Q3 2025 · Jun 30, 2024 −$74.3M
Stockholders Equity Q3 2025 · Mar 31, 2024 −$72.36M
Stockholders Equity Q3 2025 · Dec 31, 2023 −$56.51M
Current Liabilities Q3 2025 · Sep 30, 2025 $37.8M
Current Liabilities Q3 2025 · Dec 31, 2024 $22.23M
Total Liabilities Q3 2025 · Sep 30, 2025 $133.71M
Total Liabilities Q3 2025 · Dec 31, 2024 $131.44M
Current Assets Q3 2025 · Sep 30, 2025 $44.4M
Current Assets Q3 2025 · Dec 31, 2024 $37.39M
Total Assets Q3 2025 · Sep 30, 2025 $44.79M
Total Assets Q3 2025 · Dec 31, 2024 $38.34M
Eps Diluted Q3 2025 · Sep 30, 2025 −$2.18
Eps Diluted Q3 2025 · Sep 30, 2025 −$6.38
Eps Diluted restated Q3 2025 · Sep 30, 2024 −$5.15
Eps Diluted restated Q3 2025 · Sep 30, 2024 −$20.60
Eps Basic Q3 2025 · Sep 30, 2025 −$2.18
Eps Basic Q3 2025 · Sep 30, 2025 −$6.38
Eps Basic restated Q3 2025 · Sep 30, 2024 −$5.15
Eps Basic restated Q3 2025 · Sep 30, 2024 −$20.60
Sga Expense Q3 2025 · Sep 30, 2025 $5.38M
Sga Expense Q3 2025 · Sep 30, 2025 $16.69M
Sga Expense Q3 2025 · Sep 30, 2024 $7.68M
Sga Expense Q3 2025 · Sep 30, 2024 $30.4M
Rd Expense Q3 2025 · Sep 30, 2025 $8.74M
Rd Expense Q3 2025 · Sep 30, 2025 $23.55M
Rd Expense Q3 2025 · Sep 30, 2024 $5.1M
Rd Expense Q3 2025 · Sep 30, 2024 $24.53M
Net Income Q3 2025 · Sep 30, 2025 −$30.91M
Net Income Q3 2025 · Sep 30, 2025 −$57.35M
Net Income Q3 2025 · Jun 30, 2025 −$19.19M
Net Income Q3 2025 · Mar 31, 2025 −$7.25M
Net Income Q3 2025 · Sep 30, 2024 −$13.65M
Net Income Q3 2025 · Sep 30, 2024 −$48.74M
Net Income Q3 2025 · Jun 30, 2024 −$8.3M
Net Income Q3 2025 · Mar 31, 2024 −$26.79M
Operating Income Q3 2025 · Sep 30, 2025 −$14.23M
Operating Income Q3 2025 · Sep 30, 2025 −$40.18M
Operating Income Q3 2025 · Sep 30, 2024 −$15.29M
Operating Income Q3 2025 · Sep 30, 2024 −$56.75M
Cost Of Revenue Q3 2025 · Sep 30, 2025 $11K
Cost Of Revenue Q3 2025 · Sep 30, 2025 $132K
Cost Of Revenue Q3 2025 · Sep 30, 2024 $1.17M
Cost Of Revenue Q3 2025 · Sep 30, 2024 $1.31M
Revenue Q3 2025 · Sep 30, 2025 $98K
Revenue Q3 2025 · Sep 30, 2025 $386K
Revenue Q3 2025 · Sep 30, 2024 $214K
Revenue Q3 2025 · Sep 30, 2024 $1.9M